A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Upadacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-EARLY
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Planned End Date changed from 1 Feb 2021 to 1 Mar 2021.
- 18 Feb 2017 The trial has been completed in Finland.